Maindet Caroline, Minier Laure, Chipon Emilie, Véloso Mélanie, Dumolard Anne, Barmaki Mario, Lorenzi-Pernot Alberta, Gonon-Demoulian Raphaël, Ginies Patrick, Viseux Frédéric, Lemaire Antoine, Michel-Cherqui Mireille, Deleens Rodrigue, Serrie Alain, Bosson Jean-Luc, Crouzier David
Pain Medicine Department, Grenoble Alpes University Hospital, Grenoble, France.
TIMC Laboratory CNRS-UMR 5525, Grenoble Alpes University, Grenoble, France.
Medicine (Baltimore). 2025 Mar 7;104(10):e41706. doi: 10.1097/MD.0000000000041706.
This study assessed the efficacy of a therapy combining a millimeter wave emitting wristband and coaching in improving the quality of life (QoL) of Fibromyalgia (FM) patients, compared to standard care.
An open, randomized clinical trial enrolled 170 patients with FM (2016 American College of Rheumatology criteria, Fibromyalgia Impact Questionnaire score ≥ 39) from 8 French pain centers, and compared Immediate versus Delayed therapy. Therapy was provided at inclusion (D0) and month three (M3) in the Immediate and Delayed groups respectively. Therapy in the Immediate group stopped from month six (M6) to month nine (M9). Randomization was stratified by center, and FM severity, allocation ratio was 1:1. The primary outcome compared the proportion of patients with a Fibromyalgia Impact Questionnaire reduction ≥ 14% (minimal clinically important difference), from D0 to M3 in both groups. Pain (Visual Analogic Scale), sleep (Pittsburg sleep quality index), anxiety and depression (Hospital Anxiety and Depression Scale), fatigue (Multidimensional Fatigue Inventory Questionnaire), patients' and clinicians' impression of change (patient global impression of change & clinician global impression of change), physical activity (Global Physical Activity Questionnaire), generic QoL (euroqol, 5 dimensions, 5 levels), pharmacological and complementary treatment intakes, and healthcare requirements were measured at M3, M6, and M9.
At M3, 38/69 (55.1%) and 28/78 (35.9%) patients in the Immediate and Delayed groups respectively achieved the minimal clinically important difference (P = .021). There were also significant improvements in sleep quality, pain, anxiety, depression, general and physical fatigue in the Immediate versus the Delayed group at M3. These benefits persisted at M6.
Our results demonstrate that combined millimeter wave-based neuromodulation and coaching improve the QoL and other symptoms of patients with FM after 3 and 6 months.
本研究评估了与标准护理相比,一种结合毫米波发射腕带和指导的疗法在改善纤维肌痛(FM)患者生活质量(QoL)方面的疗效。
一项开放、随机临床试验纳入了来自8个法国疼痛中心的170例FM患者(符合2016年美国风湿病学会标准,纤维肌痛影响问卷评分≥39),比较了即时治疗与延迟治疗。即时组和延迟组分别在纳入时(D0)和第3个月(M3)接受治疗。即时组的治疗在第6个月(M6)至第9个月(M9)停止。随机分组按中心和FM严重程度分层,分配比例为1:1。主要结局比较了两组从D0到M3时纤维肌痛影响问卷评分降低≥14%(最小临床重要差异)的患者比例。在M3、M6和M9时测量疼痛(视觉模拟量表)、睡眠(匹兹堡睡眠质量指数)、焦虑和抑郁(医院焦虑抑郁量表)、疲劳(多维疲劳量表问卷)、患者和临床医生对变化的印象(患者总体变化印象和临床医生总体变化印象)、身体活动(全球身体活动问卷)、一般生活质量(欧洲生活质量量表,5维度,5等级)、药物和辅助治疗的摄入量以及医疗需求。
在M3时,即时组和延迟组分别有38/69(55.1%)和28/78(35.9%)的患者达到最小临床重要差异(P = 0.021)。在M3时,即时组与延迟组相比,睡眠质量、疼痛、焦虑、抑郁、总体和身体疲劳也有显著改善。这些益处持续到M6。
我们的结果表明,基于毫米波的神经调节和指导相结合,在3个月和6个月后可改善FM患者的生活质量和其他症状。